Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 82 | 2024 | 21025 | 2.560 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 39 | 2024 | 11712 | 1.510 |
Why?
|
Paclitaxel | 14 | 2024 | 1736 | 1.390 |
Why?
|
Neoadjuvant Therapy | 18 | 2024 | 2821 | 1.210 |
Why?
|
Genes, BRCA2 | 6 | 2020 | 603 | 0.880 |
Why?
|
Breast Neoplasms, Male | 3 | 2020 | 221 | 0.860 |
Why?
|
Camptothecin | 6 | 2024 | 590 | 0.850 |
Why?
|
BRCA1 Protein | 6 | 2021 | 1147 | 0.790 |
Why?
|
Piperazines | 10 | 2024 | 2525 | 0.770 |
Why?
|
Receptor, erbB-2 | 17 | 2024 | 2554 | 0.770 |
Why?
|
BRCA2 Protein | 5 | 2020 | 798 | 0.750 |
Why?
|
Indazoles | 1 | 2022 | 302 | 0.710 |
Why?
|
Carboplatin | 4 | 2021 | 788 | 0.690 |
Why?
|
Antineoplastic Agents | 15 | 2021 | 13630 | 0.650 |
Why?
|
Immunoconjugates | 6 | 2024 | 949 | 0.640 |
Why?
|
Cisplatin | 4 | 2021 | 1644 | 0.630 |
Why?
|
Phosphatidylinositol 3-Kinases | 12 | 2024 | 2864 | 0.610 |
Why?
|
Pyrimidines | 7 | 2024 | 3016 | 0.600 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 8 | 2024 | 895 | 0.580 |
Why?
|
Carbolines | 1 | 2018 | 288 | 0.540 |
Why?
|
Maytansine | 2 | 2021 | 86 | 0.540 |
Why?
|
Piperidines | 2 | 2022 | 1650 | 0.500 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2020 | 1096 | 0.490 |
Why?
|
Breast | 3 | 2024 | 1963 | 0.490 |
Why?
|
Neoplasm Staging | 21 | 2024 | 11152 | 0.480 |
Why?
|
Mastectomy | 9 | 2022 | 1832 | 0.380 |
Why?
|
Proto-Oncogene Proteins c-akt | 5 | 2024 | 2448 | 0.370 |
Why?
|
Mutation | 16 | 2024 | 29932 | 0.370 |
Why?
|
Clinical Protocols | 1 | 2016 | 1440 | 0.360 |
Why?
|
Female | 98 | 2024 | 391270 | 0.360 |
Why?
|
Immunotoxins | 1 | 2010 | 175 | 0.350 |
Why?
|
Anilides | 3 | 2020 | 409 | 0.340 |
Why?
|
Neoplastic Cells, Circulating | 5 | 2024 | 938 | 0.340 |
Why?
|
Receptors, Estrogen | 8 | 2024 | 2210 | 0.340 |
Why?
|
Maximum Tolerated Dose | 5 | 2021 | 877 | 0.340 |
Why?
|
Genes, BRCA1 | 5 | 2018 | 765 | 0.310 |
Why?
|
Disease-Free Survival | 11 | 2024 | 6828 | 0.310 |
Why?
|
Neoplasms | 10 | 2022 | 22072 | 0.310 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2024 | 3529 | 0.300 |
Why?
|
Humans | 114 | 2024 | 760621 | 0.290 |
Why?
|
Nitriles | 5 | 2015 | 956 | 0.280 |
Why?
|
PTEN Phosphohydrolase | 3 | 2024 | 1115 | 0.270 |
Why?
|
Benzimidazoles | 3 | 2021 | 858 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2024 | 9276 | 0.250 |
Why?
|
Lymphedema | 3 | 2019 | 524 | 0.250 |
Why?
|
Loss of Heterozygosity | 3 | 2016 | 659 | 0.240 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 74 | 0.230 |
Why?
|
Middle Aged | 50 | 2024 | 220352 | 0.230 |
Why?
|
Neoplasm Metastasis | 13 | 2021 | 4902 | 0.230 |
Why?
|
Biological Specimen Banks | 2 | 2019 | 783 | 0.220 |
Why?
|
Axilla | 4 | 2020 | 626 | 0.220 |
Why?
|
Tomography, Optical | 1 | 2024 | 129 | 0.220 |
Why?
|
Receptor, erbB-3 | 1 | 2024 | 143 | 0.220 |
Why?
|
Germ-Line Mutation | 3 | 2021 | 1841 | 0.220 |
Why?
|
Aged | 44 | 2024 | 169152 | 0.210 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2018 | 741 | 0.200 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4899 | 0.200 |
Why?
|
Placebos | 4 | 2019 | 1668 | 0.200 |
Why?
|
Lymph Nodes | 3 | 2020 | 3486 | 0.200 |
Why?
|
Hormones | 3 | 2021 | 867 | 0.190 |
Why?
|
src Homology Domains | 3 | 2003 | 361 | 0.190 |
Why?
|
Pilot Projects | 3 | 2023 | 8555 | 0.180 |
Why?
|
Combined Modality Therapy | 8 | 2021 | 8552 | 0.180 |
Why?
|
Phthalazines | 3 | 2024 | 383 | 0.180 |
Why?
|
Adult | 41 | 2024 | 219994 | 0.180 |
Why?
|
Receptors, Progesterone | 3 | 2015 | 1130 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2021 | 5253 | 0.160 |
Why?
|
Taxoids | 4 | 2024 | 669 | 0.160 |
Why?
|
Estrogen Receptor alpha | 2 | 2023 | 580 | 0.160 |
Why?
|
Antigens, Neoplasm | 6 | 2024 | 1998 | 0.160 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2019 | 1529 | 0.160 |
Why?
|
Tissue Banks | 1 | 2019 | 184 | 0.150 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 642 | 0.150 |
Why?
|
Pyridines | 3 | 2020 | 2879 | 0.150 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3085 | 0.150 |
Why?
|
Phosphoproteins | 2 | 1998 | 2440 | 0.150 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3205 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 256 | 0.150 |
Why?
|
Cryotherapy | 1 | 2019 | 161 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17790 | 0.150 |
Why?
|
GTPase-Activating Proteins | 1 | 2021 | 475 | 0.150 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9185 | 0.150 |
Why?
|
Alopecia | 2 | 2020 | 414 | 0.150 |
Why?
|
Second Messenger Systems | 1 | 1998 | 202 | 0.150 |
Why?
|
Lymph Node Excision | 2 | 2015 | 1303 | 0.150 |
Why?
|
Cell Adhesion Molecules | 6 | 2024 | 1602 | 0.150 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 936 | 0.140 |
Why?
|
Telemedicine | 3 | 2023 | 3018 | 0.140 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 2 | 1995 | 436 | 0.140 |
Why?
|
Cell Line, Tumor | 11 | 2024 | 16939 | 0.130 |
Why?
|
Double-Blind Method | 5 | 2024 | 12427 | 0.130 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2017 | 626 | 0.130 |
Why?
|
Cyclophosphamide | 2 | 2020 | 2221 | 0.130 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2005 | 2828 | 0.130 |
Why?
|
Allelic Imbalance | 1 | 2016 | 77 | 0.130 |
Why?
|
Treatment Outcome | 20 | 2024 | 65017 | 0.130 |
Why?
|
Prognosis | 9 | 2024 | 29658 | 0.120 |
Why?
|
Phosphotyrosine | 1 | 1996 | 456 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2019 | 2058 | 0.120 |
Why?
|
Receptor, trkA | 1 | 1996 | 159 | 0.120 |
Why?
|
Feasibility Studies | 3 | 2023 | 5201 | 0.120 |
Why?
|
Hypothermia, Induced | 1 | 2020 | 758 | 0.120 |
Why?
|
Monosaccharide Transport Proteins | 2 | 1995 | 440 | 0.120 |
Why?
|
Triazoles | 3 | 2015 | 904 | 0.120 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2024 | 8515 | 0.120 |
Why?
|
Fungal Proteins | 1 | 1998 | 911 | 0.120 |
Why?
|
Fluorouracil | 2 | 2020 | 1631 | 0.120 |
Why?
|
Neoplasm, Residual | 2 | 2024 | 1007 | 0.120 |
Why?
|
Schizosaccharomyces | 1 | 1996 | 237 | 0.110 |
Why?
|
Lymphatic Metastasis | 2 | 2020 | 2943 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2020 | 563 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1088 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 544 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2019 | 10827 | 0.110 |
Why?
|
Dacarbazine | 1 | 2016 | 560 | 0.110 |
Why?
|
src-Family Kinases | 1 | 1996 | 535 | 0.110 |
Why?
|
Muscle Proteins | 2 | 1995 | 1152 | 0.110 |
Why?
|
Aromatase Inhibitors | 2 | 2015 | 511 | 0.110 |
Why?
|
Tosyl Compounds | 1 | 2013 | 112 | 0.110 |
Why?
|
Enzyme Inhibitors | 2 | 2011 | 3726 | 0.110 |
Why?
|
Sample Size | 1 | 2016 | 840 | 0.110 |
Why?
|
Doxorubicin | 1 | 2020 | 2209 | 0.110 |
Why?
|
Radiodermatitis | 1 | 2013 | 58 | 0.110 |
Why?
|
Informed Consent | 1 | 2019 | 1005 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 4 | 2019 | 5643 | 0.110 |
Why?
|
Photochemotherapy | 1 | 2019 | 820 | 0.100 |
Why?
|
Gene Expression Profiling | 4 | 2018 | 9411 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3584 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2016 | 567 | 0.100 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 36 | 0.100 |
Why?
|
Stiff-Person Syndrome | 1 | 2012 | 32 | 0.100 |
Why?
|
Oxygen Consumption | 1 | 2018 | 1843 | 0.100 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2803 | 0.100 |
Why?
|
Pedigree | 1 | 2020 | 4578 | 0.100 |
Why?
|
Patient Preference | 1 | 2019 | 922 | 0.100 |
Why?
|
Adipocytes | 2 | 1995 | 1179 | 0.100 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2013 | 412 | 0.090 |
Why?
|
Genomic Instability | 1 | 2015 | 704 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2016 | 965 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2020 | 4878 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2014 | 873 | 0.090 |
Why?
|
Patient Selection | 2 | 2019 | 4283 | 0.090 |
Why?
|
Telomere | 1 | 2016 | 933 | 0.080 |
Why?
|
ROC Curve | 4 | 2024 | 3568 | 0.080 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58995 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2014 | 1069 | 0.080 |
Why?
|
Quinolines | 1 | 2014 | 759 | 0.080 |
Why?
|
Tamoxifen | 2 | 2023 | 963 | 0.080 |
Why?
|
Genomics | 3 | 2021 | 5794 | 0.080 |
Why?
|
Stromal Cells | 1 | 2014 | 1326 | 0.080 |
Why?
|
Burns | 1 | 2020 | 1866 | 0.080 |
Why?
|
Phosphatidylinositols | 2 | 2000 | 282 | 0.080 |
Why?
|
Pandemics | 4 | 2022 | 8624 | 0.080 |
Why?
|
Heterozygote | 1 | 2015 | 2798 | 0.080 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2013 | 730 | 0.070 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 2640 | 0.070 |
Why?
|
Saccharomyces cerevisiae | 1 | 1998 | 2698 | 0.070 |
Why?
|
3T3 Cells | 4 | 1996 | 1085 | 0.070 |
Why?
|
DNA Mutational Analysis | 2 | 2020 | 4107 | 0.070 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3618 | 0.070 |
Why?
|
Thiazoles | 1 | 2014 | 1511 | 0.070 |
Why?
|
Lipoproteins | 2 | 2003 | 882 | 0.070 |
Why?
|
Receptors, Androgen | 1 | 2013 | 1077 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 2 | 2015 | 2049 | 0.070 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3844 | 0.070 |
Why?
|
Glucose | 2 | 1995 | 4351 | 0.070 |
Why?
|
Anthracyclines | 1 | 2009 | 283 | 0.070 |
Why?
|
Platinum | 2 | 2020 | 223 | 0.070 |
Why?
|
Scalp | 2 | 2020 | 389 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 12965 | 0.070 |
Why?
|
Signal Transduction | 7 | 2024 | 23376 | 0.070 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2000 | 2753 | 0.070 |
Why?
|
Medical Oncology | 3 | 2022 | 2313 | 0.070 |
Why?
|
Quinazolines | 1 | 2012 | 1363 | 0.070 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2003 | 2895 | 0.060 |
Why?
|
Young Adult | 10 | 2021 | 58741 | 0.060 |
Why?
|
Retreatment | 2 | 2018 | 600 | 0.060 |
Why?
|
Cell Growth Processes | 1 | 2005 | 384 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2023 | 2919 | 0.060 |
Why?
|
Hemoglobins | 2 | 2024 | 1521 | 0.060 |
Why?
|
Androgen Antagonists | 1 | 2013 | 1442 | 0.060 |
Why?
|
Mammary Glands, Human | 1 | 2005 | 203 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.060 |
Why?
|
Mammaplasty | 4 | 2016 | 1240 | 0.060 |
Why?
|
Antigens, T-Independent | 1 | 2003 | 21 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
Mice | 10 | 2023 | 81208 | 0.060 |
Why?
|
Prospective Studies | 7 | 2024 | 54303 | 0.060 |
Why?
|
Male | 11 | 2021 | 359744 | 0.060 |
Why?
|
Disease Management | 3 | 2020 | 2514 | 0.050 |
Why?
|
Inositol Phosphates | 2 | 2000 | 176 | 0.050 |
Why?
|
Cell Membrane | 3 | 1998 | 3682 | 0.050 |
Why?
|
Research Design | 2 | 2016 | 6180 | 0.050 |
Why?
|
Neutropenia | 2 | 2019 | 884 | 0.050 |
Why?
|
DNA, Complementary | 1 | 2006 | 1991 | 0.050 |
Why?
|
Estrogen Receptor beta | 1 | 2023 | 168 | 0.050 |
Why?
|
Models, Statistical | 1 | 2016 | 5075 | 0.050 |
Why?
|
Insulin | 2 | 1995 | 6597 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1722 | 0.050 |
Why?
|
Blood Platelets | 1 | 2012 | 2520 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 631 | 0.050 |
Why?
|
Risk Assessment | 2 | 2020 | 24123 | 0.050 |
Why?
|
Albumins | 1 | 2024 | 575 | 0.050 |
Why?
|
Fatigue | 2 | 2022 | 1544 | 0.050 |
Why?
|
Survival Rate | 3 | 2019 | 12808 | 0.050 |
Why?
|
Cell Adhesion | 2 | 2005 | 3094 | 0.050 |
Why?
|
Survival Analysis | 3 | 2018 | 10182 | 0.050 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2017 | 733 | 0.050 |
Why?
|
Recurrence | 3 | 2020 | 8482 | 0.050 |
Why?
|
Indoles | 1 | 2009 | 1829 | 0.050 |
Why?
|
Ketones | 1 | 2021 | 183 | 0.040 |
Why?
|
Furans | 1 | 2021 | 199 | 0.040 |
Why?
|
Radiotherapy Dosage | 2 | 2019 | 2897 | 0.040 |
Why?
|
Time Factors | 4 | 2017 | 40165 | 0.040 |
Why?
|
Animals | 10 | 2023 | 167963 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 2 | 1998 | 3735 | 0.040 |
Why?
|
Epithelial Cells | 2 | 2013 | 3663 | 0.040 |
Why?
|
Glucose Transporter Type 4 | 2 | 1995 | 240 | 0.040 |
Why?
|
Consensus Sequence | 1 | 1998 | 365 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2004 | 910 | 0.040 |
Why?
|
Phosphatidylinositol Phosphates | 1 | 1998 | 202 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 852 | 0.040 |
Why?
|
Amenorrhea | 1 | 2021 | 480 | 0.040 |
Why?
|
Amino Acid Sequence | 3 | 2000 | 13451 | 0.040 |
Why?
|
Genotype | 3 | 2021 | 12960 | 0.040 |
Why?
|
Proteomics | 2 | 2012 | 3817 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2016 | 64 | 0.030 |
Why?
|
Glucuronosyltransferase | 1 | 2017 | 130 | 0.030 |
Why?
|
Blood Proteins | 2 | 2000 | 1173 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1827 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2018 | 6544 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2018 | 473 | 0.030 |
Why?
|
Half-Life | 1 | 2017 | 652 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2019 | 346 | 0.030 |
Why?
|
Fasting | 1 | 2022 | 1603 | 0.030 |
Why?
|
Administration, Oral | 2 | 2017 | 4035 | 0.030 |
Why?
|
Cell Survival | 1 | 2005 | 5797 | 0.030 |
Why?
|
Mastectomy, Segmental | 1 | 2021 | 972 | 0.030 |
Why?
|
Logistic Models | 3 | 2018 | 13314 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2019 | 556 | 0.030 |
Why?
|
Conserved Sequence | 1 | 1998 | 1167 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5325 | 0.030 |
Why?
|
Deoxyglucose | 1 | 1995 | 333 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2019 | 39261 | 0.030 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 1996 | 306 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2022 | 80372 | 0.030 |
Why?
|
Gene Amplification | 1 | 2019 | 1085 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2004 | 2414 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2019 | 1376 | 0.030 |
Why?
|
Biological Transport | 2 | 1995 | 2086 | 0.030 |
Why?
|
Biotechnology | 1 | 1996 | 281 | 0.030 |
Why?
|
Incidence | 3 | 2019 | 21392 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2234 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2018 | 1578 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 36290 | 0.030 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 1996 | 557 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 935 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2024 | 6465 | 0.030 |
Why?
|
Focus Groups | 1 | 2019 | 1378 | 0.030 |
Why?
|
Hemodynamics | 1 | 2024 | 4174 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10344 | 0.030 |
Why?
|
Quinoxalines | 1 | 2015 | 297 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2018 | 510 | 0.030 |
Why?
|
Mammography | 1 | 2024 | 2427 | 0.030 |
Why?
|
ras Proteins | 1 | 1998 | 1052 | 0.030 |
Why?
|
Platelet-Derived Growth Factor | 1 | 1995 | 617 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1791 | 0.030 |
Why?
|
Enzyme Activation | 2 | 1996 | 3602 | 0.030 |
Why?
|
Triage | 1 | 2020 | 987 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 1995 | 695 | 0.030 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1996 | 1693 | 0.030 |
Why?
|
Reflex, Abnormal | 1 | 2012 | 83 | 0.030 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 102 | 0.030 |
Why?
|
Platelet Factor 4 | 1 | 2012 | 129 | 0.030 |
Why?
|
Spasm | 1 | 2012 | 131 | 0.030 |
Why?
|
Diarrhea | 1 | 2019 | 1319 | 0.020 |
Why?
|
Cell Movement | 3 | 2013 | 5206 | 0.020 |
Why?
|
Models, Molecular | 2 | 2000 | 5434 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12531 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2020 | 2326 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.020 |
Why?
|
Kinetics | 2 | 1998 | 6377 | 0.020 |
Why?
|
Receptor, Insulin | 1 | 1995 | 836 | 0.020 |
Why?
|
Vinblastine | 1 | 2013 | 487 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2932 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2013 | 312 | 0.020 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2012 | 102 | 0.020 |
Why?
|
Review Literature as Topic | 1 | 2013 | 349 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 1995 | 951 | 0.020 |
Why?
|
Fertility | 1 | 2016 | 773 | 0.020 |
Why?
|
Morpholines | 1 | 2014 | 583 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 1995 | 1246 | 0.020 |
Why?
|
Point Mutation | 1 | 1996 | 1594 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 1791 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 4166 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3598 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 1996 | 4169 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 4938 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2003 | 4742 | 0.020 |
Why?
|
Aminopyridines | 1 | 2014 | 564 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 749 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2017 | 4541 | 0.020 |
Why?
|
Photography | 1 | 2013 | 530 | 0.020 |
Why?
|
Precipitin Tests | 2 | 2003 | 814 | 0.020 |
Why?
|
Mesoderm | 1 | 2013 | 672 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1511 | 0.020 |
Why?
|
Photons | 1 | 2013 | 581 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.020 |
Why?
|
Protein Binding | 2 | 1998 | 9335 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2014 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13308 | 0.020 |
Why?
|
Cell Count | 1 | 2013 | 1835 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2003 | 7850 | 0.020 |
Why?
|
Back Pain | 1 | 2012 | 543 | 0.020 |
Why?
|
Cell Cycle | 1 | 1996 | 2934 | 0.020 |
Why?
|
Mice, Nude | 1 | 2014 | 3607 | 0.020 |
Why?
|
Radiotherapy | 1 | 2015 | 1504 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3616 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2000 | 17624 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3775 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 4573 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2380 | 0.020 |
Why?
|
Gene Expression | 2 | 1996 | 7588 | 0.020 |
Why?
|
Antigens, CD | 1 | 1996 | 4000 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10181 | 0.020 |
Why?
|
Sulfonamides | 1 | 2015 | 1977 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1719 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 1996 | 2873 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3880 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2014 | 2007 | 0.020 |
Why?
|
Memory Disorders | 1 | 2012 | 1197 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 1959 | 0.020 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1996 | 489 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2010 | 749 | 0.010 |
Why?
|
Stroke Volume | 1 | 2018 | 5523 | 0.010 |
Why?
|
Antibodies | 1 | 2012 | 2421 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2634 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2023 | 18137 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8056 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9716 | 0.010 |
Why?
|
Alleles | 1 | 2014 | 6898 | 0.010 |
Why?
|
Molecular Probe Techniques | 1 | 2003 | 117 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 2013 | 7593 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.010 |
Why?
|
Proteins | 1 | 1996 | 6029 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3484 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8469 | 0.010 |
Why?
|
United States | 2 | 2022 | 72461 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1744 | 0.010 |
Why?
|
Binding Sites | 2 | 2000 | 6048 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6068 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18416 | 0.010 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2003 | 545 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2003 | 1753 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2004 | 1900 | 0.010 |
Why?
|
Hydrogen Bonding | 1 | 2000 | 291 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2012 | 4407 | 0.010 |
Why?
|
Phospholipase C delta | 1 | 1998 | 7 | 0.010 |
Why?
|
Antibody Formation | 1 | 2003 | 1400 | 0.010 |
Why?
|
Calorimetry | 1 | 1998 | 129 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41335 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15687 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 25942 | 0.010 |
Why?
|
Cell Differentiation | 1 | 1995 | 11481 | 0.010 |
Why?
|
Type C Phospholipases | 1 | 1998 | 287 | 0.010 |
Why?
|
Protein Structure, Secondary | 1 | 2000 | 1229 | 0.010 |
Why?
|
Shc Signaling Adaptor Proteins | 1 | 1996 | 46 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13502 | 0.010 |
Why?
|
Integrin alphaV | 1 | 1996 | 55 | 0.010 |
Why?
|
GRB2 Adaptor Protein | 1 | 1996 | 101 | 0.010 |
Why?
|
Serum Response Factor | 1 | 1996 | 78 | 0.010 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 1996 | 119 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3804 | 0.010 |
Why?
|
Substrate Specificity | 1 | 2000 | 1792 | 0.010 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 1996 | 186 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2000 | 2176 | 0.010 |
Why?
|
Culture Media, Serum-Free | 1 | 1995 | 148 | 0.010 |
Why?
|
Crystallography, X-Ray | 1 | 2000 | 1982 | 0.010 |
Why?
|
Body Mass Index | 1 | 2013 | 12914 | 0.010 |
Why?
|
rac GTP-Binding Proteins | 1 | 1995 | 162 | 0.010 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 1998 | 854 | 0.010 |
Why?
|
Isoenzymes | 1 | 1998 | 1690 | 0.010 |
Why?
|
CHO Cells | 1 | 1996 | 1389 | 0.010 |
Why?
|
Androstadienes | 1 | 1995 | 348 | 0.010 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 1995 | 444 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1998 | 3084 | 0.010 |
Why?
|
Cricetinae | 1 | 1996 | 2427 | 0.010 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 1996 | 788 | 0.010 |
Why?
|
Fatty Acids | 1 | 2000 | 1804 | 0.010 |
Why?
|
Ligands | 1 | 1998 | 3276 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15697 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20509 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 1996 | 1726 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 1996 | 2418 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1996 | 6538 | 0.000 |
Why?
|
Risk Factors | 1 | 2013 | 74359 | 0.000 |
Why?
|
Brain | 1 | 2012 | 26951 | 0.000 |
Why?
|
Rats | 1 | 1998 | 23711 | 0.000 |
Why?
|
Nuclear Proteins | 1 | 1996 | 5791 | 0.000 |
Why?
|
Apoptosis | 1 | 1996 | 9501 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 1996 | 9585 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 11903 | 0.000 |
Why?
|